Cargando…

Three-gene predictor of clinical outcome for gastric cancer patients treated with chemotherapy

To identify transcriptional profiles predictive of the clinical benefit of cisplatin and fluorouracil (CF) chemotherapy to gastric cancer patients, endoscopic biopsy samples from 96 CF-treated metastatic gastric cancer patients were prospectively collected before therapy and analyzed using high-thro...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, H K, Choi, I J, Kim, C G, Kim, H S, Oshima, A, Yamada, Y, Arao, T, Nishio, K, Michalowski, A, Green, J E
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3321506/ https://www.ncbi.nlm.nih.gov/pubmed/21173787 http://dx.doi.org/10.1038/tpj.2010.87

Ejemplares similares

A Gene Expression Signature of Acquired Chemoresistance to Cisplatin and Fluorouracil Combination Chemotherapy in Gastric Cancer Patients
por: Kim, Hark Kyun, et al.
Publicado: (2011)

FGFR2 gene amplification and clinicopathological features in gastric cancer
por: Matsumoto, K, et al.
Publicado: (2012)

Expression of thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection
por: Choi, J-H, et al.
Publicado: (2001)

miRNA signature associated with outcome of gastric cancer patients following chemotherapy
por: Kim, Chang Hee, et al.
Publicado: (2011)

Docetaxel (Taxotere), cisplatin, UFT, and leucovorin combination chemotherapy in advanced gastric cancer
por: Oh, S C, et al.
Publicado: (2005)

Expression of multidrug resistance-associated protein1,P-glycoprotein, and thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection
por: Choi, J-H, et al.
Publicado: (2002)

Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma
por: Park, S R, et al.
Publicado: (2006)

Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy
por: Fanotto, Valentina, et al.
Publicado: (2018)

Activin A inhibits vascular endothelial cell growth and suppresses tumour angiogenesis in gastric cancer
por: Kaneda, H, et al.
Publicado: (2011)

Phase II study of capecitabine and irinotecan combination chemotherapy in patients with advanced gastric cancer
por: Baek, J H, et al.
Publicado: (2006)

Differential roles of STAT3 depending on the mechanism of STAT3 activation in gastric cancer cells
por: Okamoto, W, et al.
Publicado: (2011)

Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer
por: Lee, S-H, et al.
Publicado: (2004)

A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer
por: Park, Y H, et al.
Publicado: (2004)

Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer
por: Kim, S T, et al.
Publicado: (2005)

Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab
por: Lee, Choong-Kun, et al.
Publicado: (2017)

Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy
por: Lee, D-W, et al.
Publicado: (2013)

Adenosine triphosphate-based chemotherapy response assay-guided chemotherapy in unresectable colorectal liver metastasis
por: Hur, H, et al.
Publicado: (2012)

Gastric lymphangioma.
por: Kim, H. S., et al.
Publicado: (2001)

A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer
por: Kang, H J, et al.
Publicado: (2008)

MET amplification as a potential therapeutic target in gastric cancer
por: Kawakami, Hisato, et al.
Publicado: (2012)

c-Myc expression is related with cell proliferation and associated with poor clinical outcome in human gastric cancer.
por: Han, S., et al.
Publicado: (1999)

Multicenter phase II study of docetaxel plus oxaliplatin combination chemotherapy in patients with advanced gastric cancer: Daegu Gyeongbuk Oncology Group
por: Kim, J G, et al.
Publicado: (2008)

Biomarker analysis in stage III–IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival
por: Kim, J-S, et al.
Publicado: (2009)

Chemotherapy in Elderly Patients with Gastric Cancer
por: Kim, Hyeong Su, et al.
Publicado: (2016)

D-Dimer Can Serve as a Prognostic and Predictive Biomarker for Metastatic Gastric Cancer Treated by Chemotherapy
por: Go, Se-Il, et al.
Publicado: (2015)

Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients
por: Kim, S T, et al.
Publicado: (2018)

High TOP2B/TOP2A expression ratio at diagnosis correlates with favourable outcome for standard chemotherapy in acute myeloid leukaemia
por: Song, J H, et al.
Publicado: (2012)

Inter-institutional heterogeneity in outcomes of chemotherapy for metastatic gastric cancer: correlative study in the JCOG9912 phase III trial
por: Kurokawa, Y, et al.
Publicado: (2016)

Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: A population-based outcomes study
por: Choi, In Sil, et al.
Publicado: (2018)

REG Iα is a biomarker for predicting response to chemotherapy with S-1 plus cisplatin in patients with unresectable stage IV gastric cancer
por: Sekikawa, A, et al.
Publicado: (2013)

Phase II study of capecitabine and cisplatin as first-line combination therapy in patients with gastric cancer recurrent after fluoropyrimidine-based adjuvant chemotherapy
por: Kang, H J, et al.
Publicado: (2005)

Clinical outcomes of TS-1 chemotherapy for advanced and recurrent gastric cancer
por: Lee, Sung Ryol, et al.
Publicado: (2011)

Editorial: The use of chemotherapy in treating gastric cancers
por: Huang, Lei, et al.
Publicado: (2022)

Pathologic and Oncologic Outcomes in Locally Advanced Gastric Cancer with Neoadjuvant Chemotherapy or Chemoradiotherapy
por: An, Ji Yeong, et al.
Publicado: (2013)

Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum
por: Yoon, D H, et al.
Publicado: (2012)

Analysis of treatment outcomes according to the cycles of adjuvant chemotherapy in gastric cancer: a retrospective nationwide cohort study
por: Kim, Tae-Hwan, et al.
Publicado: (2022)

MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome
por: Lee, H E, et al.
Publicado: (2012)

Combination chemotherapy of oral 5'-deoxy-5-fluorouridine and cisplatin in advanced gastric cancer: a phase II study.
por: Ahn, M. J., et al.
Publicado: (1998)

Prognostic significance of E-cadherin/catenin complex expression in gastric cancer.
por: Joo, Y. E., et al.
Publicado: (2000)

Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy
por: Lee, Suee, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_etri17nq2fvsl2c4shocuakaec